Viscoelastometry to Manage Bleeding in Liver Disease

Samantha Wilson; Joanne Joseph; Mark Danta; David J Rabbolini

doi:10.7759/cureus.41401

Viscoelastometry to Manage Bleeding in Liver Disease

Cureus. 2023 Jul 5;15(7):e41401. doi: 10.7759/cureus.41401. eCollection 2023 Jul.

Authors

Samantha Wilson¹, Joanne Joseph^{2

3}, Mark Danta^{1

4}, David J Rabbolini^{5

6}

Affiliations

¹ Gastroenterology and Hepatology, School of Clinical Medicine, St. Vincent's Healthcare Campus, Faculty of Medicine, University of New South Wales, Sydney, AUS.
² Hematology, School of Clinical Medicine, St. Vincent's Healthcare Campus, Faculty of Medicine, University of New South Wales, Sydney, AUS.
³ Hematology, St. Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Sydney, AUS.
⁴ Gastroenterology and Hepatology, St. Vincent's Hospital, Sydney, AUS.
⁵ Faculty of Medicine and Health, University of Sydney, Sydney, AUS.
⁶ Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, GBR.

Abstract

A state of "re-balanced haemostasis" describes complex coagulation changes that arise in patients with liver disease. Changes include alterations in procoagulant and anticoagulant proteins, platelets and von Willebrand factor, as well as the fibrinolytic system. Various circumstances including infection, trauma, or surgery may disrupt this balance and predispose an individual to bleeding or thrombosis. The prothrombin time, international normalised ratio, and activated partial thromboplastin time are conventional coagulation screening tests that are routinely employed by clinicians to investigate unexplained bleeding, monitor anticoagulation, and inform preoperative assessments of bleeding risk. These standard coagulation tests assess quantitative defects in procoagulant clotting factors and are insensitive to levels of natural anticoagulants, which together with procoagulant factors, are often perturbed in liver disease. Therefore, the prolongation of clotting times measured by these tests often does not reflect the multifaceted alterations of haemostasis in these patients. Viscoelastic testing (VET) provides a more encompassing assessment of clotting function by recording real-time viscoelastic changes in whole blood and includes parameters that provide information on coagulation factor function, platelet contribution to clot formation, as well as fibrinolysis. To date, VET has been employed to predict and inform transfusion support in obstetric, trauma, and cardiac surgical fields, and its use in patients undergoing liver transplantation is well established. The ability of VET to accurately predict bleeding risk and precisely guide transfusion algorithms for patients with liver disease undergoing other invasive procedures or experiencing bleeding complications has been the topic of research over the last decade. This review is a critical summary of this data and provides a detailed snapshot of the position of VET as a clinical tool in patients with liver disease.

Keywords: bleeding; cirrhosis; liver disease; thrombosis; viscoelastometry.

Publication types

Review